Modification of Timolol Release From Silicone Hydrogel Model Contact Lens Materials Using Hyaluronic Acid

Contact LensesHyaluronic Acid (HA) also known as hyaluronate is a mucopolysaccharide that occurs naturally in our bodies. It binds to water which results in a viscous gel and has been involved in literally thousands of trials in ophthalmology and orthopedics due to its ability to naturally bind to water and lubricate tissue. Believe it or not it was first patented in 1942 and most agree no other molecule has such remarkable qualities that benefit the human body and it is highly concentrated in the vitreous but in the 5th decade our body stops producing HA. Unfortunately here in the US we have not seen one successful study approved by the FDA for therapeutic ophthalmic use while in the EU, there are multiple products readily available. Several studies from over the pond have shown HA has an extremely beneficial effect in dry eye disease (DED) patients and the molecule has the ability to reduce osmolarity of the tear film for up to 3 hours; which in some cases is 50% longer that other tear supplements. I do have to be honest and report a couple of OTC drops currently available in the US have a low percentage of hyaluronate labeled as “a carrier” which is good, but having a therapeutic dose would be so much better for our patients, right?

In the current September 2014 Eye & Contact Lens, Guidi et al report results titled “Modification of timolol release from silicone hydrogel model contact lens materials using hyaluronic Acid”. The objective was to evaluate the ability of hyaluronic acid (HA) to act as a functional additive in model silicone hydrogel contact lenses to alter the uptake and release characteristics of timolol was investigated. Four different model lens compositions were explored: unmodified controls, lenses containing HA, lenses that were molecularly imprinted with timolol maleate, and those that were both imprinted and contained HA. This is an exciting step into the future for those that have access to this wonderful molecule outside the US that can not only help dry eye patients but even glaucoma patients. One has to wonder how long it will be before we can get access here.

You can read the abstract here.

Oral Azithromycin Versus Doxycycline in Meibomian Gland Dysfunction: A Randomised Double Masked Open Label Clinical Trial

Pills Spilling out of Pill Bottle

How often do you offer oral prescription antibiotic therapy to your meibomian gland dysfunction (MGD) patients? Many of us have become quite surprised by the effect we see in our dry eye disease (DED) patients we treat with oral OTC products e.g. … [Continue reading]

Mimetogen Pharmaceuticals Announces Topline Results of Its Second Clinical Study with MIM-D3 for Dry Eye Syndrome

Senior doctor/scientist using his tablet computer at work (color

Well, we may have a new drug for our dry eye disease (DED) patients sometime in the near future. However, the press release from Sept. 9, 2014 is not absolutely clear: "Mimetogen Pharmaceuticals Announces Topline Results of Its Second Clinical Study … [Continue reading]

Evaluation of Tearing in Oculoplastics Assisted by Tear Osmolarity Measurement.

oculoplastics

Since we now have several point-of-care tests available to assist in diagnosing and managing dry eye disease (DED) patients, which will certainly become standard-of-care in the near future, it is interesting to see this publication in the October … [Continue reading]

Prevalence and Risk Factors of Dry Eye Disease in a British Female Cohort

Senior Woman Applying Eye Drops

I am not a big fan of questionnaires as often times they can provide confounding factors. However in the Sept. 2014 British Journal of Ophthalmology, a publication titled "Prevalence and risk factors of dry eye disease in a British female cohort” by … [Continue reading]

Tear Osmolarity Testing and the Contact Lens Patient

tear osmolarity testing protocol dave geffen.fw

In the latest edition of 'In My Practice', Dr. David Geffen explains how Tear Osmolarity Testing can be a great asset for contact lens patients. Due to the dry eye symptoms and discomfort contact lenses can cause, patients who wear them are being … [Continue reading]

Antioxidant and Inflammatory Cytokine in Tears of Patients with Dry Eye Syndrome Treated with Preservative-free Versus Preserved Eye Drops

two medical bottles

In the busy rush of daily practice, we sometimes forget about the importance of non preserved (NP) or Preservative-free (PF) drops for our dry eye disease (DED) patients. In the July 2014 volume of Investigative Ophthalmology and Vision Science … [Continue reading]

An Indispensable Guide to Dry Eye Disease

michael lemp.fw

The Ocular Surface Journal recently published what Dr. Michael Lemp is calling an indispensable guide to a new understanding of Dry Eye Disease. Entitled 'Rethinking Dry Eye Disease: A Perspective on Clinical Implications', Lemp adds that the … [Continue reading]

Topical Administration of Lacritin is a Novel Therapy for Aqueous-deficient Dry Eye Disease.

Optometry concept

While we continue to search for a new therapeutic drug for our dry eye disease (DED) patients to be approved by the FDA, another potential prospect emerges from a new research endeavor by Vijmasi et al found in Investigative Ophthalmology and Vision … [Continue reading]

Longitudinal Changes in Tear Fluid Lipidome Brought About by Eyelid-warming Treatment in a Cohort of Meibomian Gland Dysfunction

Close-up of a beautiful blond wearing an eye mask

Simple things we can offer our patients many times result in significant benefit. We know meibomian gland dysfunction (MGD) is a leading cause of evaporative dry eye and ocular discomfort characterized by an unstable tear film principally attributed … [Continue reading]